By David Linthicum
The cloud-first strategy has now found its way into Global 5000 companies. Although cost savings is the battle cry, most enterprises try to align their existing and future workloads with mostly public cloud platforms. They are, in essence, taking an approach where the cloud should always be considered. Most of the time, they push away traditional approaches.
As organizations focus their IT spending on cloud computing, they’ll begin to migrate their workloads from corporate owned data centers to purpose-built facilities, managed and run by enterprise cloud providers. Oracle predicts that corporate-owned data center numbers will fall 80 percent by 2025, and the same percentage of IT spending will be devoted to cloud services.
By Rhucha Kulkarni
Increasingly, organizations are deploying core applications in the cloud to meet never-ending customer expectations. Often, in a bid to be ready for the future, organizations are seen jumping onto the cloud bandwagon without giving it much thought. Such haste to be on the cloud may lead overriding of some critical steps such as potential assessment, cost-benefit analysis, valuation for the customer, internal operational efficiency and so on. Organizations must avoid this tendency to jump the gun and treat cloud enablement as just another investment-heavy project; they must assess the costs and value to be gained, in both the short and long run.
By Rick Delgado
We constantly hear about programs such as Race for the Cure, Breast Cancer Awareness Month, The Ice Bucket Challenge, and other fundraising or awareness initiatives for diseases. However, hearing a disease has been cured almost never happens. With billions of dollars being used to research diseases around the world, many people started looking for reasons as to why more progress hasn’t been made. Researchers re-examined their processes and realised two things. First, research methods have been largely unchanged in many disease-fighting fields. Foundations, doctors and researchers would conduct studies independent from any other group studying the same disease and draw conclusions from their limited data set.